San Francisco, CA, United States of America

Minke Binners


Average Co-Inventor Count = 2.0

ph-index = 1

Forward Citations = 17(Granted Patents)


Company Filing History:


Years Active: 2014

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Minke Binners: Innovator in Antibody Therapeutics

Introduction

Minke Binners is a notable inventor based in San Francisco, CA, recognized for his significant contributions to the field of biopharmaceuticals. With a focus on enhancing therapeutic methods, he has developed a groundbreaking patent that aims to address critical health issues through innovative antibody technology.

Latest Patents

Minke Binners holds a patent titled "Antibodies to LRP6." This patent details anti-LRP6 antibodies and antigen-binding fragments that can effectively modulate Wnt signaling pathways. These antibodies are designed to enhance Wnt activity and counteract Dkk1 activity, which is pivotal in treating diseases related to bone disorders, gastrointestinal diseases, and wound healing. The therapeutic applications of his invention extend to addressing conditions such as osteoporosis, rheumatoid arthritis, osteolytic lesions associated with osteoarthritis and multiple myeloma.

Career Highlights

Minke Binners is currently affiliated with Arca Biopharma, Inc., where he plays a vital role in advancing research in antibody therapeutics. His educational background and expertise in the life sciences have paved the way for innovative solutions to pressing medical challenges. With one patent to his name, he continues to contribute to the growth of biopharmaceutical innovations.

Collaborations

Throughout his career, Binners has collaborated with talented professionals, including his coworker Arie Abo. Together, they work on research initiatives that explore potent new therapies aimed at modulating Wnt/LRP6 signaling, enhancing tissue homeostasis and promoting regeneration.

Conclusion

Minke Binners exemplifies the spirit of innovation in the biopharmaceutical industry. His patent on anti-LRP6 antibodies represents a significant leap in therapeutic options for several debilitating conditions. As he continues to collaborate and innovate within Arca Biopharma, his contributions will undoubtedly help shape the future of medical treatments.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…